Can We Determine The Optimal Cycle Length for Which Half-Cycle Correction Should Always Be Applied?

• Autorzy: Robert Drzał , Daria Szmurło , Mark Parker , Robert Plisko , Magdalena Władysiuk
• Języki publikacji: EN

Abstrakty

EN

The aim of the study is to measure the influence of cycle length and progression rates on differences between final results obtained using different approaches concerning time of transition to another state in Markov models (at the beginning, at the end of the cycle or half-cycle correction - HCC) and to estimate an optimal cycle length for which HCC should always be applied. A hypothetical, two-state Markov model was built. Assuming different progression rates, four methods concerning time of transition were compared. For each rate, the threshold values were determined, i.e. the maximal cycle length for which the difference between HCC/ 'life-table' (LT) method and 'beginning'/'end' methods were not greater than 5%. Cycles longer than the estimated threshold are assumed to imply the application of HCC/LT. Under few assumptions, the threshold cycle length for annual progression of 0.05 was 1 year or 2 years, for 5% and 0% discount rate, respectively. The threshold cycle lengths became shorter for lower progression rates (2 weeks for 0.90 rate). The results obtained for single intervention cannot be easily repeated for incremental outcomes; however, some general relationships can be determined(original abstract)

Słowa kluczowe

EN

Markov models; Measurement

PL

Modele Markowa; Pomiary

• Czasopismo: Journal of Health Policy and Outcomes Research
• Rocznik: 2014
• Numer: nr 2
• Strony: 64--75

Twórcy

autor

Robert Drzał

• HTA Consulting, Krakow, Poland

autor

Daria Szmurło

• HTA Consulting, Krakow, Poland

autor

Mark Parker

• University of Liverpool Management School, United Kingdom

autor

Robert Plisko

• HTA Consulting, Krakow, Poland

autor

Magdalena Władysiuk

• HTA Consulting, Krakow, Poland

Bibliografia

• Sonnenberg FA., Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993; 13(4): 322-38
• Briggs A., Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998; 13(4): 397-409
• Wisløff T., Hagen G., Rand-Hendriksen K. Half-Cycle Correction and Simpson's Method Tested in Real Health Economic Models - Does it Matter Which Method We Use? 2011
• Barendregt JJ. The Half-Cycle Correction: Banish Rather Than Explain It. Med Decis Making. 2009; 29(4): 500-2
• Taylor M., Lewis L. The Half-Cycle "Correction": How Much of a Correction is it? ISPOR 15th Annual European Congress. 2012 Nov, Berlin, Germany; Available from: http://www.ispor.org/research_pdfs/42/pdffiles/PRM48.pdf
• NICE. Specification for manufacturer/sponsor submission of evidence. 2012; Available from: https://www.nice.org.uk/proxy/?sourceurl=http://www.nice.org.uk/aboutnice/howwework/devnicetec/specificationformanufacturersponsorsubmissionofevidence.jsp
• Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. Version. 4.4. 2013; Available from: http://www.pbac.pbs.gov.au/content/information/printable-files/pbacg-book.pdf
• Agency for Health Technology Assessment. Guidelines for conducting Health Technology Assessment (HTA). Version 2.1. Warsaw 2009; Available from: http://www.aotm.gov.pl/www/assets/files/wytyczne_hta/2009/Guidelines_HTA_eng_MS_29062009.pdf
• Pharmaceutical Management Agency. Prescription for Pharmacoeconomic Analysis. Methods for cost-utility analysis. Version 2.1. New Zealand; 2012; Available from: http://www.pharmac.health.nz/assets/pfpa-final.pdf
• Delea TE., Sofrygin O., Palmer JL. et al. Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria. J Am Soc Nephrol. 2009; 20(10): 2205-13
• Rothberg MB., Virapongse A., Smith KJ. Cost-Effectiveness of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Clin Infect Dis. 2007; 44(10): 1280-8
• Geisler BP., Egan BM., Cohen JT., et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol. 2012; 60(14): 1271-7
• Golicki D., Niewada M., Jakubczyk M., Wrona W., Hermanowski T. Self-assessed health status in Poland: EQ-5D findings from the Polish valuation study. Pol Arch Med Wewn. 2010; 120(7-8): 276-81
• Barton PM. The Irrelevance of Half-Cycle Correction in Markov Models. 31st Annual Meeting of the Society for Medical Decision Making. 2009 Oct 18-21, Los Angeles, USA; Available from: https://smdm.confex.com/smdm/2009ca/webprogram/Paper4912.html
• Siebert U., Alagoz O., Ahmed M., et al. State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Value Health. 2012; 15(6): 812-20
• Dorenkamp M., Bonaventura K., Leber AW., et al. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension. Eur Heart J. 2013; 34(6): 451-61
• Johansson P. A model for economic evaluations of smoking cessation interventions - technical report. Stockholm Centre for Public Health; 2004
• NICE technology appraisal guidance 242. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy. 2012. Available from: http://www.nice.org.uk/guidance/ta242\
• Edwards S., Barton S., Thurgar E., et al. Bevacizumab for the treatment of recurrent advanced ovarian cancer. STA report. 2013; Available from: http://www.nets.nihr.ac.uk/__data/assets/pdf_file/0004/82615/ERGReport-11-40-01.pdf
• Naimark DMJ., Bott M., Krahn M. The half-cycle correction explained: two alternative pedagogical approaches. Med Decis Making. 2008; 28(5): 706-12

Identyfikatory

DOI

10.7365/JHPOR.2014.2.8